Frazier Life Sciences Management, L.P.
CIK 1892134 · View on SEC EDGAR ↗
- Portfolio value
- $4.6B
- Positions
- 41
- As of
- June 30, 2026
#857 of 9,443 by 13F value · top 9.1%
Portfolio value QoQ: +18.2% 13F does not disclose cash
- Top 10 holdings weight
- 73.61%
- Top 25 holdings weight
- 93.39%
- Positions above 1%
- 22
- Effective number of positions
- 11.8
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 7.98% Est. buys $338,273,394 · sells $349,584,619
Median holding: 4.0 quarters Tracked Q4 2024–Q2 2026 · 51.9% still held
- New positions
- 6
- Increased
- 8
- Decreased
- 2
- Closed
- 3
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +68.8% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 96.9% · Options excluded: 0.0%
Sector breakdown
Healthcare
98.0%
Other/Unmapped
2.0%
Full portfolio 41 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $899,060,606 | 19.58% | 7,679,684 | $189,611,398 | |||
| NAMS NewAmsterdam Pharma Company N.V. - Ordinary Shares | $613,032,889 | 13.35% | 18,088,902 | $70,662,683 | Up ×1 | ||
| ERAS Erasca, Inc. - Common Stock | $457,545,444 | 9.96% | 24,975,188 | $58,300,902 | Up ×2 | ||
| MBX MBX Biosciences, Inc. - Common Stock | $367,191,118 | 8.00% | 6,652,013 | $168,628,530 | |||
| ARQT Arcutis Biotherapeutics, Inc. - Common stock | $258,909,678 | 5.64% | 9,874,511 | $26,266,199 | |||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $185,370,687 | 4.04% | 9,939,447 | $66,791,891 | Down ×2 | ||
| KRYS Krystal Biotech, Inc. - Common Stock | $178,887,373 | 3.90% | 481,307 | $54,556,149 | |||
| MAZE Maze Therapeutics, Inc. - Common Stock | $150,182,184 | 3.27% | 5,032,915 | $13,849,055 | Up ×1 | ||
| PHAT Phathom Pharmaceuticals, Inc. - Common Stock | $135,261,406 | 2.95% | 12,466,489 | $-3,241,287 | |||
| PVLA Palvella Therapeutics, Inc. - Common Stock | $134,848,368 | 2.94% | 882,400 | $24,857,208 | |||
| BBIO BridgeBio Pharma, Inc. - Common Stock | $115,305,393 | 2.51% | 1,548,139 | $-140,753,409 | Down ×3 | ||
| IRON Disc Medicine, Inc. - Common Stock | $99,093,875 | 2.16% | 1,354,852 | $12,464,638 | |||
| CYTK Cytokinetics, Incorporated - Common Stock | $98,810,092 | 2.15% | 1,159,879 | $22,362,467 | |||
| DYN Dyne Therapeutics, Inc. - Common Stock | $70,029,951 | 1.53% | 3,153,082 | $12,864,574 | |||
| ASND Ascendis Pharma A/S - American Depositary Shares | $60,053,342 | 1.31% | 225,155 | $29,556,085 | Up ×1 | ||
| SVRA Savara, Inc. - Common Stock | $59,880,448 | 1.30% | 9,720,852 | $6,804,596 | |||
| Unknown issuer (CUSIP: 698955101) | $52,572,433 | 1.14% | 1,920,805 | Up ×1 | |||
| AURA Aura Biosciences, Inc. - Common Stock | $50,410,000 | 1.10% | 7,100,000 | $16,291,000 | Up ×1 | ||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $49,724,879 | 1.08% | 7,614,836 | Up ×1 | |||
| VOR Vor Biopharma Inc. - Common Stock | $46,833,917 | 1.02% | 2,543,939 | $1,450,045 | |||
| ALLO Allogene Therapeutics, Inc. - Common Stock | $46,689,069 | 1.02% | 22,446,668 | $37,425,199 | Up ×1 | ||
| TARS Tarsus Pharmaceuticals, Inc. - Common Stock | $45,860,853 | 1.00% | 728,644 | $-5,253,524 | |||
| BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | $40,092,400 | 0.87% | 4,009,240 | $1,924,435 | |||
| ALKS Alkermes plc - Ordinary Shares | $36,710,400 | 0.80% | 700,647 | $11,935,522 | |||
| ACAD ACADIA Pharmaceuticals Inc. - Common Stock | $36,386,409 | 0.79% | 1,438,198 | $4,372,122 | |||
| ZLAB Zai Lab Limited - American Depositary Shares | $36,144,080 | 0.79% | 1,902,320 | $361,441 | |||
| MNKD MannKind Corporation - Common Stock | $28,116,000 | 0.61% | 6,600,000 | $13,661,000 | Up ×2 | ||
| DSGN Design Therapeutics, Inc. - Common Stock | $26,188,587 | 0.57% | 1,809,854 | ||||
| ACRS Aclaris Therapeutics, Inc. - Common Stock | $26,055,228 | 0.57% | 4,925,374 | $7,585,075 | |||
| STTK Shattuck Labs, Inc. - Common Stock | $26,025,000 | 0.57% | 3,750,000 | Up ×1 | |||
| Unknown issuer (CUSIP: 482931102) | $24,233,000 | 0.53% | 1,100,000 | Up ×1 | |||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $24,200,000 | 0.53% | 1,000,000 | $7,750,000 | |||
| LXEO Lexeo Therapeutics, Inc. - Common Stock | $22,459,095 | 0.49% | 4,824,725 | $-2,938,827 | Up ×1 | ||
| RLAY Relay Therapeutics, Inc. - Common Stock | $19,003,616 | 0.41% | 1,015,693 | Up ×1 | |||
| EOLS Evolus, Inc. - Common Stock | $18,256,815 | 0.40% | 2,630,665 | $7,444,782 | |||
| IMCR Immunocore Holdings plc - American Depositary Shares | $15,391,829 | 0.34% | 484,782 | $775,652 | |||
| VALN Valneva SE - American Depositary Shares | $11,985,413 | 0.26% | 2,291,666 | $-2,337,500 | |||
| NAMSW NewAmsterdam Pharma Company N.V. - Warrant | $10,692,116 | 0.23% | 500,333 | $665,443 | |||
| AUTL Autolus Therapeutics plc - American Depositary Shares | $7,116,656 | 0.15% | 4,447,910 | $978,540 | |||
| Unknown issuer (CUSIP: 98422T209) | $4,047,598 | 0.09% | 422,505 | $494,331 | |||
| IBIO iBio, Inc. - Common Stock | $3,418,567 | 0.07% | 1,953,467 | $-293,020 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| MIRM | Price move only | +0 | +$189.6M |
| MBX | Price move only | +0 | +$168.6M |
| BBIO | Trimmed | -1.9M | -$140.8M |
| NAMS | Bought more | +1.1M | +$70.7M |
| TRVI | Trimmed | -100 | +$66.8M |
| ERAS | Bought more | +300K | +$58.3M |
| KRYS | Price move only | +0 | +$54.6M |
| ASND | Bought more | +92K | +$29.6M |
| ARQT | Price move only | +0 | +$26.3M |
| PVLA | Price move only | +0 | +$24.9M |
1 position hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| VRNA | Dec. 31, 2025 | 3,383,950 | $361,101,305 | No longer tracked |
| KALV | June 30, 2026 | 4,961,108 | $99,867,104 | No longer tracked |
| RNA | March 31, 2026 | 983,125 | $70,912,806 | -1.6% |
| RVMD | June 30, 2026 | 675,686 | $65,710,464 | 16.4% |
| ABVX | March 31, 2026 | 378,300 | $51,015,647 | 7.8% |
| AGIO | June 30, 2026 | 1,256,080 | $42,493,186 | -4.5% |
| RYTM | June 30, 2025 | 678,760 | $35,953,917 | 86.0% |
| SLNO | June 30, 2025 | 499,159 | $35,664,911 | No longer tracked |
| EWTX | March 31, 2025 | 1,271,245 | $33,942,242 | 110.1% |
| RAPT | March 31, 2026 | 983,333 | $33,305,489 | No longer tracked |
| RARE | Dec. 31, 2025 | 983,715 | $29,590,147 | 14.8% |
| HLVX | Sept. 30, 2025 | 10,617,062 | $21,127,953 | No longer tracked |
| ANAB | March 31, 2025 | 1,573,719 | $20,836,040 | 220.8% |
| CGON | Sept. 30, 2025 | 770,000 | $20,020,000 | 94.8% |
| MREO | Dec. 31, 2025 | 9,440,112 | $19,446,631 | -26.5% |
| AKRO | Dec. 31, 2025 | 366,784 | $17,414,904 | No longer tracked |
| PCVX | Dec. 31, 2025 | 474,405 | $17,088,068 | 34.9% |
| MRUS | June 30, 2025 | 373,100 | $15,703,779 | No longer tracked |
| PLRX | March 31, 2025 | 1,120,803 | $14,760,976 | -12.2% |
| COGT | Sept. 30, 2025 | 1,734,601 | $12,454,435 | 162.0% |
| JBIO | Dec. 31, 2025 | 1,413,280 | $12,196,606 | 50.4% |
| ASMB | Dec. 31, 2025 | 456,249 | $11,679,974 | -3.4% |
| ORIC | Sept. 30, 2025 | 1,065,334 | $10,813,140 | 19.6% |
| ADVM | Dec. 31, 2025 | 2,077,431 | $9,410,762 | No longer tracked |
| TVTX | March 31, 2026 | 241,592 | $9,231,230 | 118.5% |
| DAWN | March 31, 2025 | 689,655 | $8,737,929 | No longer tracked |
| ENGN | Dec. 31, 2025 | 1,157,380 | $7,904,905 | -80.6% |
| ETNB | March 31, 2025 | 1,000,000 | $7,820,000 | No longer tracked |
| ACAD | June 30, 2025 | 470,338 | $7,812,314 | 42.1% |
| RCKT | June 30, 2025 | 1,079,025 | $7,197,097 | 44.7% |
| ORKA | Sept. 30, 2025 | 583,327 | $6,539,096 | 469.6% |
| IMTX | June 30, 2025 | 1,247,911 | $5,628,079 | 71.6% |
| ARVN | March 31, 2025 | 285,331 | $5,469,795 | 36.6% |
| MGNX | Dec. 31, 2025 | 3,175,665 | $5,335,117 | 159.3% |
| SLN | Dec. 31, 2025 | 970,130 | $5,034,975 | 131.3% |
| DSGN | March 31, 2026 | 521,000 | $4,886,980 | 50.5% |
| ELDN | March 31, 2025 | 1,176,735 | $4,848,148 | 7.7% |
| XLO | March 31, 2026 | 5,915,091 | $3,786,841 | 10.5% |
| CBIO | Dec. 31, 2025 | 272,951 | $3,245,387 | 46.7% |
| ELEV | Sept. 30, 2025 | 5,993,579 | $2,200,243 | No longer tracked |